Transcriptome analysis reveals the clinical significance of CXCL13 in Pan-Gyn tumors

Author:

Ding Yue,Zhou Quan,Ding Bo,Zhang Yang,Shen Yang

Abstract

Abstract Background Gynecologic and breast tumors (Pan-Gyn) exhibit similar characteristics, and the role of CXCL13 in anti-tumor immunity and it’s potential as a biomarker for immune checkpoint blockade (ICB) therapy have been gradually revealed. However, the precise role of CXCL13 in Pan-Gyn remains unclear, lacking a systematic analysis. Methods We analyzed 2497 Pan-Gyn samples from the TCGA database, categorizing them into high and low CXCL13 expression groups. Validation was conducted using tumor expression datasets sourced from the GEO database. Correlation between CXCL13 and tumor immune microenvironment (TIME) was evaluated using multiple algorithms. Finally, we established nomograms for 3-year and 5-year mortality. Results High expression of CXCL13 in Pan-Gyn correlates with a favorable clinical prognosis, increased immune cell infiltration, and reduced intra-tumor heterogeneity. Model was assessed using the C-index [BRCA: 0.763 (0.732–0.794), UCEC: 0.821 (0.793–0.849), CESC: 0.736 (0.684–0.788), and OV: 0.728 (0.707–0.749)], showing decent prediction of discrimination and calibration. Conclusion Overall, this study provides comprehensive insights into the commonalities and differences of CXCL13 in Pan-Gyn, potentially opening new avenues for personalized treatment.

Funder

Beijing Xisike Clinical Oncology Research Foundation

Publisher

Springer Science and Business Media LLC

Reference54 articles.

1. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R (2018) A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33(4):690–705. https://doi.org/10.1016/j.ccell.2018.03.014

2. Cannistra SA, Pujade-Lauraine E (2019) Progress and promise in treating gynecologic cancers. J Clin Oncol 37(27):2383–2385. https://doi.org/10.1200/JCO.19.01097

3. Chung SH, Woldenberg N, Roth AR, Masamed R, Conlon W, Cohen JG, Joines MM, Patel MK (2020) BRCA and beyond: comprehensive image-rich review of hereditary breast and gynecologic cancer syndromes. Radiographics 40(2):306–325. https://doi.org/10.1148/rg.2020190084

4. Cosgrove J, Novkovic M, Albrecht S, Pikor NB, Zhou Z, Onder L, Morbe U, Cupovic J, Miller H, Alden K, Thuery A, O’Toole P, Pinter R, Jarrett S, Taylor E, Venetz D, Heller M, Uguccioni M, Legler DF, Lacey CJ, Coatesworth A, Polak WG, Cupedo T, Manoury B, Thelen M, Stein JV, Wolf M, Leake MC, Timmis J, Ludewig B, Coles MC (2020) B cell zone reticular cell microenvironments shape CXCL13 gradient formation. Nat Commun 11(1):3677. https://doi.org/10.1038/s41467-020-17135-2

5. Harris BS, Bishop KC, Kuller JA, Ford AC, Muasher LC, Cantrell SE, Price TM (2020) Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause 27(2):243–248. https://doi.org/10.1097/GME.0000000000001447

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3